glp-1 patient assistance program On July 1, the Medicare Bridge launches, offering new obesity treatment access. Join one of the June 18 briefings to learn more! Hosted by @obesitycareadvocacy, @amdiabetesassn, @obesityaction, @omasocial, @asmbs. Info GLP-1 Collective a Nonprofit Dedicated

Yes, many patients remain on GLP-1 therapy long-term because obesity meets the clinical definition of a chronic disease requiring ongoing management

Retatrutide, a single peptide targeting GIP, GLP-1, and glucagon receptors, has shown remarkable results in early-phase studies

Your clinician will help you weigh your own risks of side effects with the likely benefits of treatment to help you decide if taking a GLP-1 RA makes sense for you

For Melanotan II, available data (largely from early-stage and non-registered studies) suggest a plasma half-life on the order of about 30 minutes to a couple of hours, with many sources clustering around roughly 1 hour

For precise dosing, calculate expected doses as (total volume minus 0.5 mL) divided by target dose volume

Overall effect on skin, hair, nails, and joints